Cochlear Recall of Ear Implant May Cost A$100 Million, UBS Says

Cochlear Ltd.’s recall of its N5 ear implants may cost about A$100 million, UBS AG (UBSN) health-care analysts Andrew Goodsall and Dan Hurren said in a report today.

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.